STEK Stemtech Corp
Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1511820 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.9%
TTM net income YoY-18.7%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-26.6%
Net income 3-yr CAGR—
Margins
Gross margin75.7%
Operating margin-134.0%
Net margin-191.3%
FCF margin-35.5%
EBITDA margin-124.8%
Returns
ROE—
ROA-102.2%
ROIC (approx.)—
Asset turnover0.53x
Leverage & solvency
Liabilities / assets361.0%
Debt / equity—
Current ratio0.05x
Interest coverage-2.62x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-83.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.88M | $5.05M | $4.92M | $4.56M | $4.32M |
| Cost of revenue | $566,940 | $1.33M | $1.00M | $1.16M | $1.02M |
| Gross profit | $2.31M | $3.73M | $3.92M | $3.40M | $3.30M |
| R&D expense | $0 | $0 | $13,800 | $0 | — |
| SG&A expense | $4.55M | $5.23M | $6.44M | $6.84M | $4.75M |
| Operating income | -$2.71M | -$2.39M | -$4.22M | -$5.02M | -$3.21M |
| Interest expense | $1.45M | $1.58M | $4.89M | — | $8.33M |
| Pretax income | -$4.05M | -$3.77M | -$5.43M | -$8.54M | -$7.11M |
| Income tax | $0 | $0 | $0 | $95,618 | $0 |
| Net income | -$4.05M | -$3.77M | -$5.43M | -$8.54M | -$7.08M |
| EBITDA | -$2.54M | -$2.04M | -$3.64M | -$4.58M | -$2.78M |
| EPS (basic) | -0.02 | -0.03 | -0.07 | -0.19 | -0.20 |
| EPS (diluted) | -0.02 | -0.03 | -0.07 | -0.19 | -0.20 |
| Weighted avg. shares (diluted) | 169.82M | 118.70M | 83.47M | 46.01M | 35.31M |
| Balance sheet | |||||
| Cash & equivalents | $238,245 | $255,298 | $114,166 | $132,487 | $828,206 |
| Inventory | $217,338 | $197,355 | $48,325 | $158,053 | $436,405 |
| Current assets | $457,062 | $921,746 | $400,710 | $612,370 | $1.60M |
| PP&E, net | $0 | $0 | $10,056 | $27,296 | $33,168 |
| Goodwill | $467,409 | $467,409 | $467,409 | $467,409 | $467,409 |
| Intangibles | $2.21M | $2.38M | $2.71M | $2.99M | $3.41M |
| Total assets | $3.15M | $3.78M | $3.68M | $4.27M | $5.72M |
| Current liabilities | $10.59M | $8.74M | $6.46M | $7.42M | $9.39M |
| Long-term debt | $4.16M | $3.82M | $3.49M | $929,131 | — |
| Total debt | $4.16M | $3.82M | $3.49M | $929,131 | — |
| Total liabilities | $10.59M | $8.74M | $6.46M | $7.44M | $9.73M |
| Shareholders' equity | -$6.96M | -$4.48M | -$2.04M | -$2.43M | -$3.36M |
| Net debt | $3.92M | $3.56M | $3.37M | $796,644 | — |
| Shares outstanding | 425.98M | 135.76M | 104.99M | 53.44M | 44.69M |
| Cash flow statement | |||||
| Operating cash flow | -$483,583 | -$601,198 | -$2.04M | -$1.22M | -$1.91M |
| Capital expenditure | $0 | $0 | $0 | — | — |
| Free cash flow | -$483,583 | -$601,198 | -$2.04M | — | — |
| Investing cash flow | $0 | $0 | $0 | — | — |
| Financing cash flow | $460,010 | $1.08M | $1.58M | $338,734 | $2.63M |
| Depreciation & amortization | $167,495 | $344,466 | $587,797 | $447,386 | $428,586 |
| Stock-based compensation | $439,054 | $440,256 | $439,054 | $4.00M | $1.03M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.